Every year on World Lymphedema Day, attention turns to a condition that affects millions of people worldwide but still remains surprisingly misunderstood. Lymphedema is not merely swelling. It is a chronic disease of the lymphatic system—an essential yet often overlooked component of human physiology.
The lymphatic system acts as the body’s drainage network. Through a delicate web of vessels and nodes, it transports lymphatic fluid, immune cells, and metabolic waste back into the bloodstream. When this system fails, fluid accumulates in the tissues. The result is lymphedema, a progressive condition characterized by swelling, chronic inflammation, and gradual tissue changes, characterized by fibrosis and adipose tissue deposition.
Why does lymphedema occur?
Lymphedema arises when lymphatic transport capacity becomes insufficient. This can happen for two main reasons, based on the etiology of defect:
Primary lymphedema is caused by developmental abnormalities of the lymphatic vessels and is considered a rare disease. Some people are born with lymphatic networks that are fewer in number, narrower, or functionally impaired. Symptoms may appear in childhood, adolescence, or adulthood.
Far more common is secondary lymphedema, which occurs when a previously healthy lymphatic system is damaged. The most frequent cause in industrialized countries is cancer treatment, particularly surgery and radiotherapy that involve lymph node removal. Breast cancer–related lymphedema of the arm is one of the best-known examples. Worldwide, parasitic infections such as lymphatic filariasis remain another major cause.
The pathology, however, extends beyond simple fluid accumulation. Persistent lymphatic dysfunction triggers a cascade of biological changes. Inflammation develops in the tissue, fat gradually accumulates, and fibrosis—scar-like tissue—forms over time. These changes make the disease self-perpetuating and increasingly difficult to treat in later stages.
Traditional management: controlling, but not curing
For decades, treatment of lymphedema has relied primarily on conservative therapy. Compression garments, specialized physiotherapy, manual lymphatic drainage, and careful skin care remain the cornerstone of management. These approaches are effective in reducing swelling and preventing complications such as infections. Yet they do not correct the underlying lymphatic dysfunction, that they cannot be curing. Patients often require lifelong therapy to control symptoms and the effectiveness of the conservative treatment can considerably vary.
A surgical turning point
In recent years, advances in microsurgery have begun to reshape the therapeutic landscape. Lymphatic reconstructive surgery aims to restore lymphatic flow rather than simply manage its consequences. Two techniques have gained particular attention and have proven both efficiency and sufficiency when applied upon careful patient selection: one is lymphaticovenous anastomosis (LVA), in which tiny lymphatic vessels—often less than half a millimeter in diameter—are connected directly to nearby veins. This creates a new pathway for lymphatic fluid to bypass blocked segments of the lymphatic system and appears most efficient for earlier stages of lymphedema, when tissue fibrosis is not excessive. Another approach is vascularized lymph node transfer, where healthy lymph nodes together with their blood supply are transplanted to the affected area. These nodes can help re-establish lymphatic drainage and may even stimulate the formation of new lymphatic vessels, due to the production of chemical molecules that support tissue regeneration.
While these procedures are not suitable for every patient, growing evidence shows that they can significantly reduce swelling, improve quality of life, and in some cases decrease dependence on compression therapy.
Quo vadis?
Where is the field heading? The future of lymphedema care likely lies in earlier diagnosis, personalized treatment strategies, and continued innovation in lymphatic surgery. Advances in imaging technologies now allow clinicians to visualize lymphatic vessels with unprecedented detail, helping identify patients who may benefit most from surgical intervention. At the same time, research into lymphatic biology is expanding rapidly. Scientists are uncovering how inflammation, immune responses, and tissue remodeling shape the progression of the disease.
Lymphedema may still be chronic, but it is no longer static. On this World Lymphedema Day, one message becomes increasingly clear: understanding the lymphatic system is opening new paths toward treatments that were unimaginable only a generation ago. The question **“quo vadis?”—where are we going?—**may finally have an encouraging answer.
Dr. Epameinondas Gousopoulos, MD, MSc, PhD is a clinician-scientist and plastic surgeon at the Department of Plastic Surgery and Hand Surgery at the University Hospital Zurich. His work focuses on lymphatic vascular biology and the treatment of lymphatic disorders such as lymphedema and lipedema, bridging basic research with clinical innovation in reconstructive microsurgery.